• 1
    Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853.
  • 2
    Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994–1998: the EuroSIDA study. Lancet 2000; 356: 291.
  • 3
    Del Amo J, Perez-Hoyos S, Moreno A, et al. Trends in AIDS and mortality in HIV-infected subjects with hemophilia from 1985 to 2003. The competing risks for death between AIDS and liver disease. J Acquir Immune Defic Syndr 2006; 41: 624.
  • 4
    Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11.
  • 5
    Weiss RA. HIV and AIDS in relation to other pandemics. EMBO Rep 2003; 4: S10.
  • 6
    Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection 1987–1999. J Acquir Immune Defic Syndr 2002; 29: 378.
  • 7
    Thio CL, Seaberq EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921.
  • 8
    Hayashi PH, Flynn N, McCurdy SA, Kuramoto IK, Holland PV, Zeldis JB. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol 1991; 33: 177.
  • 9
    Sherman KE, Freeman S, Harrison S, Andron L. Prevalence of antibody to hepatitis C virus in patients infected with the human immunodeficiency virus. J Infect Dis 1991; 163: 414.
  • 10
    Rumi MG, Colombo M, Gringeri A, Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1990; 112: 379.
  • 11
    Salmon-Ceron D, Gouëzel P, Delarocque-Astagneau E, et al. Hospitalized HIV-HCV co-infected patients. A French national survey made in June 2001. Med Mal Infect 2003; 33: 78.
  • 12
    Staples CT Jr, Rimland D, Dudlas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veteran Affairs Medical Center) Cohort Study (HAVACS): the effect of co-infection on survival. Clin Infect Dis 1999; 29: 150.
  • 13
    Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799.
  • 14
    Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121.
  • 15
    Garcia-Samaniego J, Rodriguez M, Berenguer M, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179.
    Direct Link:
  • 16
    Bruno R, Sacchi P, Filice C, Puoti M, Filice G. Hepatocellular carcinoma in HIV infected patients with chronic hepatitis. J Acquir Immune Defic Syndr 2002; 30: 535.
  • 17
    Cattelan AM, Erne E, Salatino A, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999; 29: 455.
  • 18
    Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000; 30: 227.
  • 19
    John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998; 12: 2289.
  • 20
    Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23.
  • 21
    Sulkowsky MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74.
  • 22
    Gardenswartz MH, Lerner CW, Seligson GR, et al. Renal disease in patients with AIDS: a clinicopathologic study. Clin Nephrol 1984; 21: 197.
  • 23
    Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984; 310: 669.
  • 24
    United States Renal Data System (USRDS). USRDS 2004 Annual Data Report: Atlas of End Stage Renal Disease in the United States. Bethesda, MD: The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004.
  • 25
    Winston J, Klotman P. Are we missing an epidemic of HIV associated nephropathy? J Am Soc Nephrol 1996; 7: 1.
  • 26
    Lam M, Park MC. HIV associated nephropathy beneficial effect of zidovudine therapy. N Engl J Med 1990; 323: 1775.
  • 27
    Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of US transplant centers. Transplantation 1998; 65: 1187.
  • 28
    Hirose K, Stock PG. Liver transplantation in the human immunodeficiency virus-positive patient. Curr Opin Organ Transplant 2006; 11: 241.
  • 29
    Qiu J, Terasaki PI, Waki K, Cai J, Gjertson DW. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006; 81: 1658.
  • 30
    Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988; 239: 617.
  • 31
    Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile latent viral structure. Cell 1990; 61: 213.
  • 32
    Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328: 327.
  • 33
    Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21: 265.
  • 34
    Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001; 14: 753.
  • 35
    Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV specific CD4+T cells. Nature 2002; 417: 95.
  • 36
    Silvestri G, Sodora DL, Koup RA, et al. Nonpathogenic SIV infection of sooty mangabeys is characterised by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003; 18: 441.
  • 37
    Monceaux V, Estaquier J, Fevrier M, et al. Extensive apoptosis in lymphoid organs during primary SIV infection predicts rapid progression towards AIDS. AIDS 2003; 17: 1585.
  • 38
    Silvestri G, Fedanov A, Germon S, et al. Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabeys and nonnatural rhesus macaque hosts. J Virol 2005; 79: 4043.
  • 39
    Lempicki RA, Kovacs JA, Baseler MW. Impact of HIV infection and highly active antiretroviral therapy on the kinetics of CD4 and CD8 T cell turnover in HIV infected patients. Proc Natl Acad Sci USA 2000; 97: 13778.
  • 40
    Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291.
  • 41
    Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295.
  • 42
    Pantaleo G. How immune based intervention can change HIV therapy. Nat Med 1997; 3: 483.
  • 43
    Lori F, Foli A, Groff A, et al. Optimal suppression of HIV replication by low dose hydroxyurea through the combination of antiviral and cytostatic (virostatic) mechanisms. AIDS 2005; 19: 1173.
  • 44
    Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996, 335,18: 13501356.
  • 45
    Rizzardi GP, Pantaleo G. Other approaches to combat HIV-1 infection. In: RichmanDD, ed. HIV Human Virus Guide 2002. London, UK: International Medical Press, 2002.
  • 46
    Luban J. Absconding with the chaperone: essential cyclophilin–Gag interaction in HIV-1 virions. Cell 1996; l87: 1157.
  • 47
    Yin L, Braaten D, Luban J. Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol 1998; 72: 6430.
  • 48
    Franke EK, Yuan HEH, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994; 372: 359.
  • 49
    Thali M, Bukovsky A, Kondo E. Functional association of cyclophilin A with HIV- 1 virions. Nature 1994; 372: 363.
  • 50
    Bartz SR, Hohenwalter E, Hu MK, Rich DH, Malkovsky M. Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc Natl Acad Sci USA 1995; 92: 5381.
  • 51
    Franke EK, Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag–cyclophilin A interaction. Virology 1996; 222: 279.
  • 52
    Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989; 246: 1617.
  • 53
    Streblow DN, Kitabwalla M, Malkovsky M, Pauza CD. Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. Virology 1998; 245: 197.
  • 54
    Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109: 681.
  • 55
    Khonkarly M, Tambussi G, Ciuffreda D, et al. Long term benefit of cyclosporin A coupled with highly active antiretroviral therapy in primary HIV-1 infection. Conference on Retroviruses and Opportunistic Infections, Boston, 2005.
  • 56
    Calabrese LH, Lederman MM, Spritzler J, et al. Placebo-controlled trial of cyclosporin A in HIV disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002; 29: 356.
  • 57
    Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci 1993; 696: 63.
  • 58
    Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 1991; 23: 10.
  • 59
    Ichimura H, Levy JA. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995; 211: 554.
  • 60
    Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in Peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993; 90: 8925.
  • 61
    Margolis D, Heredia A, Gaywee J, et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999; 21: 362370.
  • 62
    Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J Acquir Immune Defic Syndr 1999; 22: 406.
  • 63
    Hossain M, Coull J, Drusano GL, Margolis M. Dose proportional inhibition of HIV1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine and tenofovir. Antiviral Res 2002, 55: 41.
  • 64
    Margolis DM, Kewn S, Coull JJ, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002; 31: 45.
  • 65
    Sankatsing SU, Jurriaans S, Van Swieten P, et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naïve HIV-1 patients. AIDS 2004; 18: 1925.
  • 66
    Chapuis A, Rizzardi GP, D'Agostino C, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2001; 6: 762.
  • 67
    Ciuffreda D. Abstract 104: Single supervised treatment interruption coupled with mycophenolate mofetil therapy induces control of HIV 1 RNA replication in patients treated with HAART since primary HIV1 infection: 102 week follow up. Conference on Retroviruses and opportunistic agents, Boston, February 2005.
  • 68
    Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus- infected liver transplant recipients. J Infect Dis 2003; 188: 1412.
  • 69
    Norris S, Taylor C, Muiesan P, et al. Outcomes of liver transplantation in HIV- infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004; 10: 1271.
  • 70
    Vogel M, Voigt E, Schäfer N, et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort. Liver Transpl 2005; 11: 1515.
  • 71
    Stock PG, Roland ME, Carlson LL, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76: 370.
  • 72
    Wolters L, Niesters H, Hansen B, et al. Development of hepatitis B resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002; 24: 173.
  • 73
    Benhamou Y, Bochet M, Thibault V, et al. Long term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302.
  • 74
    Wiegand J, Tischendorf J, Nashan B, et al. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. Gastroenterology 2004; 42: 15.
  • 75
    Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348: 177.
  • 76
    Schiff E, Lai C, Hadziyannis S, Neuhaus P, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419.
  • 77
    Terrault N, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006; 12: 801.
  • 78
    Kumar MSA, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV positive patients. Kidney Int 2005; 67: 1662.
  • 79
    Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant 2006; 6: 753.
  • 80
    Brandao AB, Mariante-Neto G. Liver transplantation in HIV-positive patients: the position of the Brazilian groups. Arq Gastroenterol 2005; 42: 161.